Cardio Diagnostics Holdings Stock Today
| CDIOW Stock | USD 0.04 0.0001 0.24% |
Performance10 of 100
| Odds Of DistressOver 71
|
Cardio Diagnostics is selling for under 0.041 as of the 23rd of November 2024; that is 0.24 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0275. Cardio Diagnostics has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. Equity ratings for Cardio Diagnostics Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of January 2022 | Category Healthcare | Classification Health Care |
Cardio Diagnostics Inc. develops and manufactures a genetic and epigenetic based test for prevention and detection of cardiovascular disease. Cardio Diagnostics Inc. was founded in 2017 and is based in Chicago, Illinois. Cardio Diagnostics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. More on Cardio Diagnostics Holdings
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cardio Stock Highlights
| CEO CoFounder | Meeshanthini Dogan | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Cardio Diagnostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cardio Diagnostics' financial leverage. It provides some insight into what part of Cardio Diagnostics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cardio Diagnostics Holdings (CDIOW) is traded on NASDAQ Exchange in USA. It is located in 311 West Superior Street, Chicago, IL, United States, 60654 and employs 7 people. Cardio Diagnostics is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Cardio Diagnostics generates negative cash flow from operations
Check Cardio Diagnostics Probability Of Bankruptcy
Cardio Diagnostics Historical Income Statement
Cardio Stock Against Markets
Cardio Diagnostics Corporate Management
| Esq JD | Chief Officer | Profile | |
| Timur Dogan | Chief Officer | Profile | |
| Khullani JD | Vice Strategy | Profile | |
| MBA JD | CFO Director | Profile | |
| Khullani Abdullah | VP Strategy | Profile |
Additional Tools for Cardio Stock Analysis
When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.